Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human apotransferrin in beta-thalassemia
2014-001936-12Phase 2Terminated
- Sponsor
- Sanquin Plasma Products
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of apotransferrin in beta-thalassemia intermedia and beta thalassemia (2 arms), sponsored by Sanquin Plasma Products. Primary endpoint: Hematological response. Started Nov 2018; status: terminated.
02
Drugs
apotransferrin
03
Conditions
beta-thalassemia intermediabeta thalassemia
Beyond the preview
Go deeper on 2014-001936-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001936-12.